Show simple item record

dc.contributor.authorKlempner, Mark S.
dc.contributor.authorBaker, Phillip J.
dc.contributor.authorShapiro, Eugene D.
dc.contributor.authorMarques, Adriana
dc.contributor.authorDattwyler, Raymond J.
dc.contributor.authorHalperin, John J.
dc.contributor.authorWormser, Gary P.
dc.date2022-08-11T08:08:30.000
dc.date.accessioned2022-08-23T15:57:12Z
dc.date.available2022-08-23T15:57:12Z
dc.date.issued2013-08-01
dc.date.submitted2014-05-13
dc.identifier.citation<p>Am J Med. 2013 Aug;126(8):665-9. doi: 10.1016/j.amjmed.2013.02.014. <a href="http://dx.doi.org/10.1016/j.amjmed.2013.02.014">Link to article on publisher's site</a></p>
dc.identifier.issn0002-9343 (Linking)
dc.identifier.doi10.1016/j.amjmed.2013.02.014
dc.identifier.pmid23764268
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30142
dc.description.abstractThe authors of 4 National Institutes of Health-sponsored antibiotic treatment trials of patients with persistent unexplained symptoms despite previous antibiotic treatment of Lyme disease determined that retreatment provides little if any benefit and carries significant risk. Two groups recently provided an independent reassessment of these trials and concluded that prolonged courses of antibiotics are likely to be helpful. We have carefully considered the points raised by these groups, along with our own critical review of the treatment trials. On the basis of this analysis, the conclusion that there is a meaningful clinical benefit to be gained from retreatment of such patients with parenteral antibiotic therapy cannot be justified.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23764268&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttp://dx.doi.org/10.1016/j.amjmed.2013.02.014
dc.subjectAnti-Bacterial Agents
dc.subject*Borrelia burgdorferi
dc.subjectChronic Disease
dc.subjectClinical Trials as Topic
dc.subjectHumans
dc.subjectLyme Disease
dc.subjectTreatment Outcome
dc.subjectBorrelia burgdorferi
dc.subjectClinical trials
dc.subjectLyme disease
dc.subjectPost-Lyme disease syndrome
dc.subjectBacterial Infections and Mycoses
dc.subjectChemical Actions and Uses
dc.subjectHealth Services Administration
dc.subjectPharmaceutical Preparations
dc.subjectTherapeutics
dc.titleTreatment trials for post-Lyme disease symptoms revisited
dc.typeArticle
dc.source.journaltitleThe American journal of medicine
dc.source.volume126
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/382
dc.identifier.contextkey5574362
html.description.abstract<p>The authors of 4 National Institutes of Health-sponsored antibiotic treatment trials of patients with persistent unexplained symptoms despite previous antibiotic treatment of Lyme disease determined that retreatment provides little if any benefit and carries significant risk. Two groups recently provided an independent reassessment of these trials and concluded that prolonged courses of antibiotics are likely to be helpful. We have carefully considered the points raised by these groups, along with our own critical review of the treatment trials. On the basis of this analysis, the conclusion that there is a meaningful clinical benefit to be gained from retreatment of such patients with parenteral antibiotic therapy cannot be justified.</p>
dc.identifier.submissionpathfaculty_pubs/382
dc.contributor.departmentDepartment of Medicine
dc.source.pages665-9


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record